Finance

Lists
CMPX:NASDAQ
Compass Therapeutics Inc.
$1.14
+0.44%
(+0.0050) 1D
Sep 25, 3:07:44 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CMPX...
Open
$1.17
High
$1.20
Low
$1.14
Mkt. cap
204.40M
Avg. vol.
3.72M
Volume
2.63M
52-wk high
$6.88
52-wk low
$1.10
EPS
-$0.40
Beta
0.85
Shares outstanding
180.09M
No. of employees
39
Open
$1.17
High
$1.20
Low
$1.14
Mkt. cap
204.40M
Avg. vol.
3.72M
Volume
2.63M
52-wk high
$6.88
52-wk low
$1.10
EPS
-$0.40
Beta
0.85
Shares outstanding
180.09M
No. of employees
39
News stories
From web sources and news partners
About Compass Therapeutics Inc.
CEO-
Employees39
Founded2014
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitecompasstherapeutics.com
Analyst ratings
Based on 11 analysts giving stock ratings to CMPX in the past 3 months
Strong buy
Buy
9
Hold
2
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CMPX in the last 3 months.
Highest
Current $1.14
$12.00 (+952.63%)
Average
$6.13 (+437.72%)
Lowest
$1.00 (-12.28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Albert Lowe
Craig-Hallum
Buy
Maintained
$8.00
+601.8%
09/23/2026
John Newman
Canaccord Genuity
Buy
Maintained
$7.00
+514%
09/23/2026
Michael Schmidt
Guggenheim
Buy
Reiterated
$4.00
+250.9%
09/22/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
-
-
09/22/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$12.00
+952.6%
09/23/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$4.00
+250.9%
09/23/2026
Robert Driscoll
Wedbush
Hold
Downgraded
$1.00
-12.3%
09/23/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/22/2026
Charles Zhu
LifeSci Capital
Hold
Downgraded
-
-
09/22/2026
Biren Amin
Piper Sandler
Buy
Maintained
$6.00
+426.3%
08/07/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$7.00
+514%
08/07/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$8.00
+601.8%
05/06/2026
Sean McCutcheon
Raymond James
Hold
Downgraded
-
-
04/28/2026
Maury Raycroft
Jefferies
Buy
Maintained
$9.00
+689.5%
04/27/2026
Jonathan Chang
Leerink Partners
Buy
Maintained
$11.00
+864.9%
04/27/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$8.00
+601.8%
03/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12.83M
13.67M
13.39M
19.58M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.99M
4.32M
6.91M
7.40M
Operating expense
15.82M
17.99M
20.30M
26.98M
Total operating expenses
15.82M
17.99M
20.30M
26.98M
Operating income
-15.82M
-17.99M
-20.30M
-26.98M
Other non operating income
-
-
-
-
EBT including unusual items
-14.26M
-15.72M
-18.32M
-25.15M
EBT excluding unusual items
-14.26M
-15.72M
-18.32M
-25.15M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.26M
-15.72M
-18.32M
-25.15M
Net profit margin
-
-
-
-
Earnings per share
-0.08
-0.09
-0.10
-0.13
Interest and investment income
1.56M
2.27M
1.98M
1.82M
Interest expense
-
-
-
-
Net interest expenses
1.56M
2.27M
1.98M
1.82M
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.80M
-17.97M
-20.28M
-26.96M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps